Coronavirus Vaccines (COVID-19; SARS-COV-2): preliminary review of articles, patents, clinical trials and marke

Authors

DOI:

https://doi.org/10.9771/cp.v13i1.35871

Keywords:

Pandemic, Immunization, Microorganisms, Technological Evaluation, Biotechnology, Scientific Knowledge, COVID-19, Vaccine, Corona Virus.

Abstract

The recent Coronavirus outbreak has sparked a worldwide pandemic. This article consists of an exploratory study to assess the existing volume of material and the potential for further technological assessment and forecast. It is used to assess the knowledge that exists in science (through articles), in technology (through patents), in clinical tests and ready for use (through vaccines available on the market). The articles were mapped on the Web of Knowledge, the patent assessment used the European Worldwide database, using the Orbit® software. 991 patents, 125 articles and 115 clinical studies were found, with only 2 explicitly referring to vaccines. The annual evolution shows an exponential growth from 2002-2004 for articles and for patents. The vast majority of clinical studies have not yet started (only 15% have been completed), showing that there is an urgent need to stimulate their maturation. There is still no vaccine on the market that is considered worldwide effective.

Downloads

Download data is not yet available.

Author Biographies

Cristina M. Quintella, Federal University of Bahia, Salvador, BA, Brazil

  • Endereço para acessar este CV: http://lattes.cnpq.br/7897779819494573
  • ID Lattes: 7897779819494573

Ana Maria Tavares da Mata, ESTS-CINEA, Polytechnic Institute of Setúbal, PT; iBB, IST, University of Lisbon, Portugal

PhD in Environmental Engineering, teaches at ESTSetúbal, Polytechnic Institute of Setúbal, researcher at CINEA-IPS and IBB – Institute of Bioengineering and Bioscience (IST, UL).

Grace Ferreira Ghesti, University of Brasilia, Brasilia, DF, Brazil

Bachelor and PhD in Chemistry. He teaches in the Undergraduate course in Chemistry at the University of Brasília and in the Professional Master's Program in Intellectual Property and Technology Transfer for Innovation - PROFNIT.

Pedro Miguel de Assis Lopes Tavares da Mata, Hospital Garcia de Orta, Pragal, Almada, Portugal

Graduated in Medicine with specialization in Internal Medicine and Geriatrics (1992) at Hospital das Clínicas in São Paulo, Brazil. Specialization in Homeopathy (1995) at the São Paulo Homeopathy Association. Master in Palliative Care (2013) at Escola Superior de Saúde Prof. Lopes Dias in Portugal.

References

KAISER PERMANENTE WASHINGTON HEALTH RESEARCH INSTITUTE. Vaccines and Infectious Diseases, Seattle, Washington, United States, Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) to Prevent SARS-CoV-2 Infection, 2020. Disponível em: https://ClinicalTrials.gov/show/NCT04283461. Acesso em: 15 mar. 2020.

LAI, Chih-Cheng et al. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease-2019 (COVID-19): The Epidemic and the Challenges. International Journal of Antimicrobial Agents, [S.l.], v. 55, n. 3, 2020. DOI:10.1016/j.ijantimicag.2020.105924.

NIHCT – U. S. NATIONAL LIBRARY OF MEDICINE. Clinical Trials. [2020]. Disponível em https://clinicaltrials.gov/. Acesso em: 15 mar. 2020.

OMS – ORGANIZAÇÃO MUNDIAL DE SAÚDE. [2020a]. Disponível em: https://www.who.int/ith/diseases/sars/en/; https://www.who.int/emergencies/mers-cov/en/. Acesso em: 15 mar. 2020.

OMS – ORGANIZAÇÃO MUNDIAL DE SAÚDE. [2020b]. Disponível em: https://www.who.int/ith/diseases/sars/en/; https://www.who.int/emergencies/mers-cov/en/. Acesso em: 15 mar. 2020.

ORBIT. [2020]. Disponível em: https://www.questel.com/business-intelligence-software/orbit-intelligence/. Acesso em: 13 mar. 2020.

PANG, J. et al. Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review. Journal of Clinical Medicine, [S.l.], n. 3, p. 623, 2020. DOI 10.3390/jcm9030623.

PEERI, N. C. et al. The SARS and MERS, and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? Int J Epidemiol, [S.l.], v. 22, Feb, 2020. DOI: 10.1093/ije/dyaa033.

QUINTELLA, C. M. et al. Maturidade Tecnológica: Níveis de Prontidão TRL. In: MOURA RIBEIRO, Núbia. (org.). PROFNIT, Prospecção Tecnológica. 1. ed. Salvador, BA: Editora do IFBA, 2019. v. 2, p. 18-59. Disponível em: http://www.profnit.org.br/pt/livros-profnit/. Acesso em: 13 mar. 2020.

REMDESIVIR, 2020. University of California San Diego Health – Jacobs Medical Center, La Jolla, California, United States. University of California Irvine Medical Center – Infectious Disease, Orange, California, United States. University of California Davis Medical Center – Internal Medicine – Infectious Disease, Sacramento, California, United States. Emory Clinic – Investigational Drug Service, Atlanta, Georgia, United States. Emory Vaccine Center – The Hope Clinic, Decatur, Georgia, United States. University of Maryland School of Medicine – Center for Vaccine Development – Baltimore, Annapolis, Maryland, United States. Johns Hopkins Hospital – Medicine – Infectious Diseases, Baltimore, Maryland, United States. National Institutes of Health – Clinical Center, National Institute of Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical Research Section, Bethesda, Maryland, United States. University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine, Minneapolis, Minnesota, United States. Saint Louis University – Center for Vaccine Development, Saint Louis, Missouri, United States. University of Nebraska Medical Center – Infectious Diseases, Omaha, Nebraska, United States. Montefiore Medical Center – Infectious Diseases, Bronx, New York, United States. University of Texas Medical Branch – Division of Infectious Disease, Galveston, Texas, United States. Baylor College of Medicine – Molecular Virology and Microbiology, Houston, Texas, United States. Evergreen Health Infectious Disease Service, Kirkland, Washington, United States. The University of Washington – Virology Research Clinic, Seattle, Washington, United States. Providence Sacred Heart Medical Center, Spokane, Washington, United States. Seoul National University Bundang Hospital – Division of Infectious Diseases, Bundang-gu Seongnam-si, Gyeonggi-do, Korea, Republic of. Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of. National Centre for Infectious Diseases (NCID), Singapore, Singapore. Adaptive COVID-19 Treatment Trial. Disponível em: https://ClinicalTrials.gov/show/NCT04280705. Acesso em: 15 mar. 2020.

SCHMOCH, U. Concept of a Technology Classification for Country Comparisons. Anexo 41ª Session da Committee of Experts da Special Union for the International Patent Classification (IPC Union), World Intellectual Property Organization (WIPO), IPC/CE/41/5. 2008. Disponível em: https://www.wipo.int/edocs/mdocs/classifications/en/ipc_ce_41/ipc_ce_41_5-annex1.pdf. Acesso em: 3 jun. 2019.

TRIPS. Agreement on Trade Related Aspects of Intellectual Property Rights. [2000]. Disponível em: https://www.wto.org/english/tratop_e/trips_e/trips_e.htm. Access em: 14 fev. 2020.

Downloads

Published

2020-03-27

How to Cite

Quintella, C. M., Mata, A. M. T. da, Ghesti, G. F., & Mata, P. M. de A. L. T. da. (2020). Coronavirus Vaccines (COVID-19; SARS-COV-2): preliminary review of articles, patents, clinical trials and marke. Cadernos De Prospecção, 13(1), 3. https://doi.org/10.9771/cp.v13i1.35871

Issue

Vol. 13 No. 1 (2020)

Section

Propriedade Intelectual, Inovação e Desenvolvimento

License

Copyright (c) 2020 Cadernos de Prospecção

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

O autor declara que: - Todos os autores foram nomeados. - Está submetendo o manuscrito com o consentimento dos outros autores. - Caso o trabalho submetido tiver sido contratado por algum empregador, tem o consentimento do referido empregador. - Os autores estão cientes de que é condição de publicação que os manuscritos submetidos a esta revista não tenham sido publicados anteriormente e não sejam submetidos ou publicados simultaneamente em outro periódico sem prévia autorização do Conselho Editorial. - Os autores concordam que o seu artigo ou parte dele possa ser distribuído e/ou reproduzido por qualquer forma, incluindo traduções, desde que sejam citados de modo completo esta revista e os autores do manuscrito. - Revista Cadernos de Prospecção está licenciado com uma Licença Creative Commons Attribution 4.0. Esta licença permite que outros remixem, adaptem e criem a partir do seu trabalho para fins não comerciais, e embora os novos trabalhos tenham de lhe atribuir o devido crédito e não possam ser usados para fins comerciais, os usuários não têm de licenciar esses trabalhos derivados sob os mesmos termos. Licença Creative Commons
Este obra está licenciado com uma Licença Creative Commons Atribuição 4.0 Internacional.